Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
The purpose of this clinical research is to define the optimal uptake time of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize breast cancer somatostatin receptor subtype 2 (SSTR2) positive lesions. 68Ga-OPS202 is a radiolabelled imaging agent to be used in association with PET. 68Ga-OPS202 is made of two main components: 1) OPS202, an antagonistic somatostatin analogue which binds to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2) Gallium 68, a radioisotope that, combined with OPS202, can be seen in the PET scanner.
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
The purpose of this clinical research is to define the optimal uptake time of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize breast cancer somatostatin receptor subtype 2 (SSTR2) positive lesions. 68Ga-OPS202 is a radiolabelled imaging agent to be used in association with PET. 68Ga-OPS202 is made of two main components: 1) OPS202, an antagonistic somatostatin analogue which binds to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2) Gallium 68, a radioisotope that, combined with OPS202, can be seen in the PET scanner.
Related Clinical Trials
![A study to evaluate the effect of phenytoin or itraconazole on the circulating levels of IPN60130 in healthy adult participants A study to evaluate the effect of phenytoin or itraconazole on the circulating levels of IPN60130 in healthy adult participants](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A study to evaluate the effect of phenytoin or itraconazole on the circulating levels of IPN60130 in healthy adult participants
![A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ?14 Years With Fibrodysplasia Ossificans Progressiva...
![A study to assess whether adding maintenance cabozantinib (XL184) to best supportive care helps children, adolescents and young adults with osteosarcoma. A study to assess whether adding maintenance cabozantinib (XL184) to best supportive care helps children, adolescents and young adults with osteosarcoma.](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A study to assess whether adding maintenance cabozantinib (XL184) to best supportive care helps children, adolescents and young adults with osteosarcoma.
![A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults
![A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults
![A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
![A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
![Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
![Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)
Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
![Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/defaultImg.png)